European Knowledge Centre opened in the UK - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Knowledge Centre opened in the UK


Eisai (Japan) has opened its new European Knowledge Centre in Hertfordshire (UK) after investing approximately 117 million euro in the region to help develop new medicines for Alzheimer's Disease, Parkinson's Disease and epilepsy, as well as new treatments for cancer. The company's first ever European manufacturing facility will also be based at the centre.

"This is an exciting day for the company," said Haruo Naito, President and CEO of the company. "The newly opened centre will not only act as a hub for managing our current business across Europe; it will play an important role in supporting our operations in driving further growth for the company in Europe — one of our key investment markets."

The opening of the facility was attended by the Japanese ambassador to the UK, His Excellency Shin Ebihara, who in a press release said he was hopeful that the combined knowledge of the UK and Japan would "add a new page to the long history and excellent economic relationship between the countries." Alzheimer's disease campaigner and best-selling author Terry Pratchett was also present.

"We need to speed up research and, incidentally, the speed in which successful discoveries get to patients. Alzheimer's research started late compared with many other diseases and the wave is already breaking," said Pratchett in a press release from Eisai. "I hope everyone employed in the centre works overtime!"

www.eisai.co.jp

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here